News Agency
Men's Weekly

RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

  • Written by PR Newswire
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced that its independently developed mesothelin-targeting antibody-drug conjugate (ADC), RC88, has recently received Investigational New Drug (IND) approval from the U.S. Food and...

Read more: RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent...

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion